DOI: https://dx.doi.org/10.18203/2320-1770.ijrcog20222633
Published: 2022-10-28

Efficacy of ormeloxifene in comparison to norethisterone in the management of abnormal uterine bleeding

Suguna Srinivasan

Abstract


Background: Abnormal uterine bleeding (AUB) is the most common complaint worldwide. In India, most of the women present with menorrhagia and majority of them are anemic and require medical management to avoid its consequences. Hence this study is done to compare the efficacy of ormeloxifene with norethisterone in women presenting with AUB.

Methods: In this study 61 women suffering from AUB were included. This prospective randomized double blinded study was done on women between the age group of 19-45 years and were allocated randomly into two groups, one group was given ormeloxifene and the other was given norethisterone for a period of 3 months. Haemoglobin levels, endometrial morphology on ultrasound were assessed before and after the treatment in both the groups.

Results: It is observed in our study, that both ormeloxifene and norethisterone reduced menorrhagia. The rise in hemoglobin concentration was significantly more with ormeloxifene than norethisterone (8.3 g/dl to 10.3 g/dl versus 9.0 g/dl to 10.4 g/dl). In our study, the significant reduction in the endometrial morphology was more with ormeloxifene than norethisterone (9.3 mm to 7.8 mm versus 8.3 mm to 7.2 mm).

Conclusions: Ormeloxifene is a new modality drug and is found to be a better option in reducing menorrhagia compared with norethisterone in respect to a greater success rate, better compliance and cost effectiveness. Hence our study concludes ormeloxifene as a better choice over norethisterone in the treatment of AUB.


Keywords


Abnormal uterine bleeding, Ormeloxifene, Norethisterone, Endometrial thickness

Full Text:

PDF

References


Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383-90.

Telner DE, Jakubovicz D. Approach to diagnosis and management of abnormal uterine bleeding. Canfam Physician. 2007;53(1):58-64.

Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety Of Ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynaecol Res. 2009;35(4):746-52.

Shahab P, Jain S, Jain P, Jain U. Ormeloxifene boon to perimenopausal DUB women in avoiding hysterectomies. Int J Med Sci Educa. 2014;1(1):21-9.

Bellad Girija C, LAkshmi KS. Ormeloxifene in the management of DUB. J Evidence Based Med Health Care. 2015;2(37):6125-31.

Ravi Babu K, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res. 2013;7(11):2534-6.

Grover S, Chhabra A, Bindu S. A study of ormeloxifene in case of dysfunctional uterine Bleeding. Int J Med Dent Sci. 2013;2(2):162-9.

Agarwal N, Singh S, Singh S, Agarwal M, Manocha P. Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2013;2:194-8.

Agrawal P, Shinde U, Shinde S, Aher G. Efficacy of ormeloxifene VS Norethisterone in the management of perimenopausal DUB. VIMSHSJ. 2019;14(2):30-3.

Surabhi HD. Comparison of effectiveness of Ormeloxifene with norethisterone in perimenopausal DUB treatment. Indian J Obstet Gynecol Res. 2019;15;6(2):137-40.

Jacob KJ, Mini DA. A comparative study on the effectiveness of ormeloxifene versus Norethisterone in the management of perimenopausal dysfunctional uterine bleeding. Int Arch Integr Med. 2015;2:87-92.